Overview

A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride

Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
An escalating dose of prucalopride up to a maximum of 20 mg was given once daily to 32 healthy volunteers to determine safety at the maximum tolerable dose or at 20 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Movetis
Treatments:
Prucalopride